Real-World study tests MS drug ofatumumab in greek clinics

NCT ID NCT06486779

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 160 people with relapsing multiple sclerosis in Greece who are already taking ofatumumab (Kesimpta®) as part of their routine care. Researchers will track how many patients have no signs of disease activity—like relapses, new brain lesions, or worsening disability—over time. The goal is to see if the drug works as well in real-world settings as it did in earlier clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ofatumumab (Kesimpta®)
What this could lead to: If successful, this study could confirm that ofatumumab works as well in everyday clinics as it does in controlled trials, supporting its use for relapsing MS.
What could go wrong: This is an observational study, not a controlled experiment, so results may be influenced by patient selection or other factors. It is also limited to Greece, so findings may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING MULTIPLE SCLEROSIS (RMS)

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Athens, Attica, 15562, Greece
Novartis Investigative Site
RECRUITING

Athens, GR, 115 26, Greece
Novartis Investigative Site
RECRUITING

Alexandroupoli, 681 00, Greece
Novartis Investigative Site
RECRUITING

Athens, 115 21, Greece
Novartis Investigative Site
RECRUITING

Athens, 115 25, Greece
Novartis Investigative Site
RECRUITING

Athens, 115 27, Greece
Novartis Investigative Site
WITHDRAWN

Athens, 115 28, Greece
Novartis Investigative Site
RECRUITING

Athens, 145 61, Greece
Novartis Investigative Site
RECRUITING

Chaïdári, 124 62, Greece
Novartis Investigative Site
RECRUITING

Crete Heraklion, 714 09, Greece
Novartis Investigative Site
RECRUITING

Ioannina, 455 00, Greece
Novartis Investigative Site
RECRUITING

Larissa, 411 10, Greece
Novartis Investigative Site
RECRUITING

Pátrai, 265 04, Greece
Novartis Investigative Site
RECRUITING

Thessaloniki, 53246, Greece
Novartis Investigative Site
RECRUITING

Thessaloniki, 54636, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.